Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | HMGCR | P04035 | 2/20 | 0.52 |
| ▸ | DHCR24 | Q15392 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | NPC1L1 | Q9UHC9 | 3/20 | 0.43 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.43 |
| ▸ | EBP | Q15125 | 6/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | OSBP | P22059 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.41 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8430174 | 0.87 | USP2 (0.66) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL9766765 | 0.84 | HMGCR (0.74) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL9766761 | 0.84 | HMGCR (0.74) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL9766734 | 0.83 | USP2 (0.59) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL11490959 | 0.82 | USP2 (0.65) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL9464083 | 0.82 | USP2 (0.65) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL9464748 | 0.82 | USP2 (0.65) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL9766831 | 0.82 | TRPV1 (0.51) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL9464105 | 0.82 | USP2 (0.62) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL11412303 | 0.81 | USP2 (0.63) | USP2MEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 429 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-222914187-U | Intelligent safety Zhuo Ban and output circuit thereof | 东莞市鑫宇宸科技有限公司 | 2025-05-27 | — | — | CN | claimed |
| EP-4143613-B1 | ANTIOXIDANT CONTACT LENS | COOPERVISION INT LTD (GB) | 2025-01-08 | — | — | EP | claimed |
| EP-4455741-A2 | ANTIOXIDANT CONTACT LENS | CooperVision International Limited (GB) | 2024-10-30 | — | — | EP | claimed |
| US-12038556-B2 | Antioxidant contact lens | COOPERVISION INTERNATIONAL LIMITED (GB) | 2024-07-16 | — | — | US | claimed |
| WO-2024103178-A1 | ANISOMYCIN ANALOGS AND USES THEREOF | Université de Montréal (CA) | 2024-05-23 | — | — | WO | claimed |
| EP-3143130-B1 | CELL CULTURE MEDIA COMPOSITIONS FOR PRIMARY CELLS | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2024-03-06 | — | — | EP | claimed |
| US-20230367038-A1 | Antioxidant Contact Lens | COOPERVISION INTERNATIONAL LIMITED (GB) | 2023-11-16 | — | — | US | claimed |
| CN-115461652-B | Antioxidant contact lens | 库博光学国际有限公司 | 2023-11-14 | — | — | CN | claimed |
| US-11754753-B2 | Antioxidant contact lens | COOPERVISION INTERNATIONAL LIMITED (GB) | 2023-09-12 | — | — | US | claimed |
| EP-4143613-A1 | ANTIOXIDANT CONTACT LENS | CooperVision International Limited (GB) | 2023-03-08 | — | — | EP | claimed |
| CN-115461652-A | Oxidation resistant contact lenses | 库博光学国际有限公司 | 2022-12-09 | — | — | CN | claimed |
| US-20260139018-A1 | MODULATION OF WNT SIGNALLING IN CORNEAL DISORDERS | SURROZEN OPERATING INC (US) | 2026-05-21 | — | — | US | disclosed |
| CN-122060112-A | Ophthalmic poly-nitroxide amphoteric ion nano-drug carrier, nano-preparation and application | 安徽中医药大学 | 2026-05-19 | — | — | CN | disclosed |
| CN-122031439-A | Application of isoliquiritigenin and/or glabridin in preparation of medicine for treating acanthamoeba infection | 上海市重大传染病和生物安全研究院 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026101986-A1 | IRRADIATED EXTRACELLULAR VESICLES AND METHODS OF MAKING AND USING SAME | HENRY FORD HEALTH SYSTEM (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2022025239-A1 | METHOD FOR ENHANCING THERAPEUTIC EFFECT OF CORNEAL ENDOTHELIAL CELL INJECTION THERAPY | 学校法人同志社 | 2022-02-03 | — | — | WO | disclosed |
| WO-2022025240-A1 | METHOD AND VESSEL FOR PRESERVING CORNEAL ENDOTHELIAL CELLS | 学校法人同志社 | 2022-02-03 | — | — | WO | disclosed |
| US-20220024891-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-01-27 | — | — | US | disclosed |
| WO-2022018605-A1 | A FORMULATION OF COMBINATION OF GENISTEIN AND CALCITRIOL FOR MANAGEMENT OF INFLAMMATORY OCULAR SURFACE CONDITIONS | Narayana Nethralaya Foundation (IN) | 2022-01-27 | — | — | WO | disclosed |
| EP-3344232-B1 | MICELLES FOR MUCOADHESIVE DRUG DELIVERY | UNIV MCMASTER (CA) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024891-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | APC, VHL, KRAS | USP2 1644/4885MEN1 480/4885KMT2A 2351/4885 |
| US-20260139018-A1 | MODULATION OF WNT SIGNALLING IN CORNEAL DISORDERS | WNT3A, WNT3, SFRP1 | USP2 1655/4885MEN1 4758/4885KMT2A 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.